Group Sessions Lowered Diabetes Risk Factors

BY MIRIAM E. TUCKER
FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

ORLANDO — A community-based lifestyle intervention program significantly reduced body weight and waist circumference and lowered fasting blood glucose levels at 1 year compared with usual care in a study of 301 adults with prediabetes.

Results of the Healthy Living Partnerships to Prevent Diabetes (HELP PD) study were presented by Dr. David C. Goff, chair of the department of epidemiology and prevention at Wake Forest University. The intervention was modeled after the landmark Diabetes Prevention Program (DPP) study, in which individuals at high risk for type 2 diabetes who received individual lifestyle counseling had a 58% reduction in the development of diabetes over 3 years (N. Engl. J. Med. 2002;346:393-403). Both studies were funded by the National Institute of Diabetes and Digestive and Kidney Diseases.

"In the 7 years since publication of the DPP, there has been great interest in developing and testing ways to translate those behavioral weight loss approaches to community settings in ways that can reach the large population of people with prediabetes," Dr. Goff said during a press briefing at the meeting.

In HELP PD, the DPP intervention was modified to a group-based counseling session with about 10-14 people per group. In another difference, specially trained lay community health workers who had brought their diabetes under control delivered the intervention, which included encouragement to change eating behaviors and to exercise for up to 180 minutes per week, with an emphasis on walking.

In the intervention group, sessions were held weekly for the first 6 months and monthly for the next 18 months. The usual-care group received two individual sessions with a registered dietician during the first 3 months of the study and a monthly newsletter throughout the 2 years. Telephone calls were also included.

Subjects in the intervention group lost an average of 7 kg in the first intervention year, compared with a loss of 1.5 kg in the usual-care group. Although the sample wasn’t large enough to assess the development of diabetes with statistical significance, there have been fewer cases among the intervention group participants, consistent with the 4-mg/dL reduction in fasting glucose. Monitoring for diabetes will be continued into a second year along with the other parameters, he said.

About 3,000 diabetes education programs around the country are now recognized by the ADA. In order for this intervention to take place, staff would need to be trained to administer it and policies would need to change to allow reimbursement for treatment of prediabetes, Dr. Goff noted.

Disclosures: Dr. Goff stated that he has received funding for diabetes-related research from Merck and has served on a safety monitoring board for Takeda.

07/2010 • WWW.CLINICALENDOCRINOLOGYNEWS.COM

OBESITY

23

ENG.

Obesity in the United States: Prevalence and Consequences

Obesity is a chronic condition resulting from a complex interaction of genetic, environmental, and behavioral factors. Approximately 30% of U.S. adults are estimated to be obese, defined as having a body mass index (BMI) of 30 or greater. Obesity is associated with an increased risk of chronic diseases such as diabetes, heart disease, and certain cancers. The prevalence of obesity has been increasing over the past several decades, and effective strategies are needed to address this public health problem.

Important information

NovoLog® insulin aspart (rDNA origin) injection requires pre-meal administration to help control blood glucose levels when taken with meals.

Important safety information

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or dextrose. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin. Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity. Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, edema, itching, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glucose control, may cause hypokalemia. Like all insulin analogs, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment. All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy.

To access complimentary e-learning programs, visit novomedlink.com/NovoLog.